Esperion Announces Proposed Public Offering of Common Stock
ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) — Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq:ESPR) announced today that it has commenced an underwritten public offering of shares of its common stock. In connection with this offering, Esperion expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares to be sold in the proposed offering of common stock will be sold by Esperion.